Ziopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley ’21...
May 04 2021 - 8:00AM
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq:
ZIOP), announced today that Laurence J.N. Cooper, PhD, MD,
Scientific Advisor to the Company, will present and participate in
an upcoming panel discussion at the University of Pennsylvania’s
upcoming Cellicon Valley symposium, May 6-7, 2021.
“I am excited to participate in this important
event on behalf of Ziopharm,” said Dr. Cooper. “This meeting will
bring together a wide variety of leading thinkers and researchers,
and I am looking forward to sharing my perspectives on Ziopharm’s
unique technologies.”
The panel session, entitled “Gene Delivery and
Editing for Better CARs”, will be moderated by Fyodor D. Urnov,
PhD, Professor of Molecular and Cell Biology, University of
California at Berkley.
Dr. Cooper’s remarks will focus on the
advantages of Ziopharm’s cellular therapy technologies targeting
solid tumors, including its proprietary non-viral gene transfer
system, Sleeping Beauty.
Interested parties may register for the event
using this link. Registrants will be able to view the event
beginning at 9am ET on Thursday May 6, 2021, under Conference Track
3: Pre-Clinical / Manufacturing. The live Q&A will take place
at 3:30pm ET also on May 6, 2021. Dr. Cooper’s slides will also be
posted on the Ziopharm website in the Investors section.
About Ziopharm Oncology,
Inc.Ziopharm is developing non-viral and cytokine-driven
cell and gene therapies that weaponize the body’s immune system to
treat the millions of people globally diagnosed with cancer each
year. With its multiplatform approach, Ziopharm is at the forefront
of immuno-oncology. Ziopharm’s pipeline is built for commercially
scalable, cost effective T-cell receptor T-cell therapies based on
its non-viral Sleeping Beauty gene transfer platform, a
precisely controlled IL-12 gene therapy, and rapidly
manufactured Sleeping Beauty-enabled CD19-specific CAR-T
program. The Company has clinical and strategic collaborations with
the National Cancer Institute, The University of Texas MD
Anderson Cancer Center and Regeneron Pharmaceuticals. For more
information, please visit www.ziopharm.com.
Investor Relations Contact:Adam D. Levy, Ph.D.,
MBAEVP, Investor Relations and Corporate CommunicationsT:
508.552.9255E: alevy@ziopharm.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2023 to Apr 2024